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Background: Hypertension is one of the key factors causing cardiovascular diseases. A substantial proportion of
treated hypertensive patients do not reach recommended target blood pressure values. Shared decision making
(SDM) is to enhance the active role of patients. As until now there exists little information on the effects of SDM
training in antihypertensive therapy, we tested the effect of an SDM training programme for general practitioners
(GPs). Our hypotheses are that this SDM training (1) enhances the participation of patients and (2) leads to an
enhanced decrease in blood pressure (BP) values, compared to patients receiving usual care without prior SDM
training for GPs.
Methods: The study was conducted as a cluster randomised controlled trial (cRCT) with GP practices in Southwest
Germany. Each GP practice included patients with treated but uncontrolled hypertension and/or with relevant
comorbidity. After baseline assessment (T0) GP practices were randomly allocated into an intervention and a
control arm. GPs of the intervention group took part in the SDM training. GPs of the control group treated their
patients as usual. The intervention was blinded to the patients. Primary endpoints on patient level were (1) change
of patients’ perceived participation (SDM-Q-9) and (2) change of systolic BP (24h-mean). Secondary endpoints were
changes of (1) diastolic BP (24h-mean), (2) patients’ knowledge about hypertension, (3) adherence (MARS-D), and (4)
cardiovascular risk score (CVR).
Results: In total 1357 patients from 36 general practices were screened for blood pressure control by ambulatory
blood pressure monitoring (ABPM). Thereof 1120 patients remained in the study because of uncontrolled (but
treated) hypertension and/or a relevant comorbidity. At T0 the intervention group involved 17 GP practices with
552 patients and the control group 19 GP practices with 568 patients. The effectiveness analysis could not
demonstrate a significant or relevant effect of the SDM training on any of the endpoints.
Conclusion: The study hypothesis that the SDM training enhanced patients’ perceived participation and lowered
their BP could not be confirmed. Further research is needed to examine the impact of patient participation on the
treatment of hypertension in primary care.
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Hypertension is one of the key factors causing cardiovascu-
lar diseases (CVD) [1] which make up the most frequent
cause of death in industrialised nations [2]. Though effective
antihypertensive medication is available, a substantial rate of
treated hypertensive patients exceed the (systolic/diastolic)
thresholds of 140/90 mmHg in clinical blood pressure
measurement (CBPM) and are characterised as uncon-
trolled (but treated) hypertensive. Rates of controlled treated
hypertension (below 140/90 mmHg) range from 43% to
70% in North America [3-8], 49% in Switzerland [9] and
between 25% and about 60% in Germany [10-12]. Long
term consequences of uncontrolled hypertension like stroke
or heart attack lead to high individual and societal burden.
There are two primary reasons to enhance patients’
active participation in medical decisions: (1) Patients
have the right to be fully informed on chances and risks
of treatments [13,14] and (2) therapies are presumed to
be more successful if patients are involved in decisions
[15-17]. One concept to achieve this is shared decision
making (SDM). SDM interventions are recommended
when there are several similarly effective treatment
options. This applies to the treatment of uncomplicated
arterial hypertension [1,18,19]. Although there is substantial
research on SDM, until now there exists little information
on the effects of SDM training for general practi-
tioners (GPs) on patient participation and clinical
outcomes [15-17,20-25]. This holds also for blood
pressure (BP) in antihypertensive treatment.
The aim of this study was to implement an evaluated
SDM training programme [26] for GPs within the
context of hypertension treatment, and to answer the
following research questions: Does the SDM training
for GPs (1) enhance patients’ perceived participation
and (2) lower the BP values of patients?
Methods
Trial design and participants
The study was conducted as a cluster randomised
controlled trial (cRCT). Each GP practice with its patients
was considered as one cluster. As the intervention (SDM
training for GPs) affects a GP’s communication style
which, in turn, affects all patients of a given GP, a random-
isation on patient level would have led to a contamination
of treatment conditions. While the intervention took
place on GP level, the objectives of the intervention
(e.g. enhanced participation and BP decrease) pertained to
the patient level. In this study we used ambulatory
blood pressure monitoring (ABPM) because of its
higher validity compared to CBPM [18,27,28]. Before
the first data assessment all participating GP practices
were equipped with identical ABPM instruments
(Mobil-O-Graph new generation 24h ABP-Control)
[29,30]. Under conditions of ABPM a different definitionof hypertension is required [1,28,31]. Therefore, in our
study any patient is characterised as (uncontrolled)
hypertensive whose 24h mean is ≥ 130/80 mmHg or
whose daytime mean is ≥ 135/85 mmHg or whose night
mean is ≥ 120/70 mmHg.
Inclusion and exclusion criteria
The eligibility criteria for GPs were (1) location in
Southwest Germany, (2) offering the full spectrum of
a family doctor’s health care services and (3) non-
participation in another study implementing an SDM
training as intervention. There were no other inclusion or
exclusion criteria for GP practices. Most of the participating
GPs belonged to teaching practices associated with
the Division of General Practice of the University Medical
Centre Freiburg (Germany).
Inclusion criteria for patients to be screened at T0 were
(1) repeated prescription of antihypertensive medication,
(2) age of at least 18 years, (3) insured by a statutory health
fund with the exception of ‘Bundesknappschaft and
See-health insurance’, and (4) understanding of the
German language. Exclusion criteria were dementia, mental
handicap, or short life expectancy. There were no other
inclusion or exclusion criteria for patients.
Data assessment
Data were collected at four points (T0 – T3). Baseline data
(T0) were assessed between June and December 2009.
Patients with uncontrolled hypertension (defined as 24h
mean ≥ 130/80 mmHg or daytime mean ≥ 135/85 mmHg
or night mean ≥ 120/70 mmHg) or with a relevant cardio-
vascular comorbidity (defined as diabetes mellitus, coronary
heart disease [CHD]/heart attack, stroke/transient ische-
mic attack [TIA] or peripheral arterial occlusive disease
[PAOD]) were then included in the study population.
Data of the three follow-up assessments (T1, T2 and T3)
were collected at 6, 12 and 18 months (± 2months). The
last follow-up measurement (T3) was completed in
September 2011. After completing the baseline assessment
(T0), GP practices were randomised to either intervention
(SDM training) or control group (no training, consultation
as usual).
In each of the four data assessments clinical data and
self-reported patient data were gathered.
Clinical data: Ambulatory blood pressure monitoring
(ABPM) was conducted, and values of cholesterol and
HbA1c were assessed by the GP practices so that the car-
diovascular risk (CVR) of the patients could be calculated.
After each ABPM, the BP protocol was reviewed in a
separate consultation and necessary therapy adaptations
were decided.
Self-reported patient data: In each of the four data
collections, questionnaires were distributed to the patients
by their GP practices. These questionnaires contained a
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participation in medical decisions (SDM-Q-9) [32], the
translated and validated Medication Adherence Report
Scale (MARS-D) [33], and an instrument to assess patients’
knowledge about hypertension (eight items; developed by
our research group). Furthermore, the questionnaires
referred to changes in antihypertensive therapy and treat-
ment outside the GP practice, to socio-demographic data,
tobacco consumption, height and weight. Moreover some
other self-reporting instruments [34-37] were included. All
scores of the questionnaire instruments with Likert scales
were transformed into a scale ranging from 0 (lowest level)
to 100 (highest level).
Intervention
Those GPs who had been allocated to the intervention
group took part in an SDM training programme [26]
which had been evaluated in various studies [22,23,38,39].
It was adapted to the requirements of antihypertensive
treatment in general practice and entailed six hours in
total. The training included the following elements: (1)
information on arterial hypertension, (2) physician-patient
communication and risk communication, (3) the process
steps of SDM, (4) motivational interviewing [40,41], (5)
introduction of a decision table listing options to lower
CVR, and (6) use of case vignettes for role plays
simulating physician-patient consultations. Additionally,
we recommended implementing a cardiovascular risk
calculator for GPs which included elements of SDM
[24,42]. Furthermore we delivered patient information flyers
[43] to the GPs of the intervention group. The intervention
took place before the T1 data assessment.
GPs of the control group treated their patients as
usual.
Outcomes
The outcomes of the study pertained to the patient level.
Primary endpoints were (1) change of patients’ perceived
participation from T0 to T1, T2 and T3 and (2) change
of systolic BP (24h-mean) from T1 to T2 and T3 evaluated
as the mean effect over all points in time. Secondary
endpoints were (1) change of diastolic BP (24h-mean), (2)
change of patients’ adherence, (3) change of cardiovascular
risk score (CVR), each from T1 to T2 and T3, and (4)
change of patients’ knowledge on hypertension from T0
to T1, T2 and T3. All endpoints were analysed using
mixed models [44]. Additionally, the proportion of
patients whose BP was uncontrolled at each time
point were analysed descriptively.
Randomisation
To prevent an allocation bias on cluster level and a
subsampling bias on patient level, randomisation took
place after the baseline assessment [45]. We randomlyselected GP practices (including their patients) for the
intervention or control group, respectively. The randomisa-
tion was conducted by staff members of the Division of
General Practice, University Medical Centre Freiburg. No
stratification was used. The patients were blinded to the
allocation of the intervention (single-blinded study).
Sample size and power calculation
Power and sample size considerations have been pub-
lished in the study protocol [46]. In brief, we intended to
include 1200 patients in the study population so that
after a 20% drop out at the practice level and a 20% drop
out at the patient level we could expect to be able to
include 788 patients in the final analysis. This would
allow detection of effect sizes of 0.3 or 0.35 with a power
of 74% or 87%, respectively, assuming an ICC of 0.05
(VIF = 2.15) and using a Bonferroni correction for the
two primary outcomes.
Missing data
The primary endpoints ‘change of perceived participa-
tion’ and ‘change of systolic blood pressure’ were analysed
according to the intention-to-treat (ITT) principle. Ac-
cording to Kriston et al. [32] missing data in SDM-Q-9
were replaced if there were at most two missing items.
Imputation was realised by using the mean of the valid
items (on patient level). Subsequently the raw score was
calculated and transformed into a scale ranging from 0 to
100. ABPM values were considered valid for a given point
in time if ABPM data of at least 7 nocturnal and 14 day-
time measurements had been reported. Missing ABPM
data were not replaced (for details cf. study protocol [46]).
The exploration of the complete dataset showed that for
some endpoints, non-response was slightly higher in the
control group than in the intervention group. But overall
we found no systematic patterns of missing data.
Statistical analysis of endpoints
Primary and secondary endpoints are defined as change
from baseline. For SDM-Q-9 and knowledge on hyperten-
sion, the respective T0 data were considered as baseline
values, since the intervention may affect both outcomes
directly at the first visit after intervention (T1). In contrast
systolic and diastolic BP, CVR, and MARS-D cannot
be affected by the intervention before the second visit
after intervention. Therefore, the respective T1 data
were considered as baseline values for these outcomes
(for details cf. study protocol [46]). The intervention
effect was evaluated as mean effect over all follow-ups
using a mixed effects model (adjusted for the respective
baseline values of outcomes according to European
Medicine Agency (EMA) guideline [47]), where repeated
measurements and clustering are dealt with by random
effects. All patients contributing a baseline value and at
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mixed model analysis.
Two kinds of sensitivity analyses were performed: (1)
All endpoints whose baseline values had been calculated
from T1 data in the main analysis (BP, CVR, and
MARS-D) were re-analysed by using T0 data as baseline.
(2) Both primary endpoints were re-analysed adjusting
for several prognostic factors (for details on analyses see
study protocol [46]). A descriptive analysis was done to
illustrate the proportion of patients with uncontrolled
(but treated) hypertension at each time point.
Statistical programming was performed with the
Statistical Analysis System (SAS) Version 9.2.
Ethics
Interested GPs and their medical assistants were
informed orally and via printed material about the
study and data protection. GPs who wanted to take
part in the study confirmed via a written consent
form. Patients were informed about the study by their
GPs. If patients agreed to take part in the study, both
patient and GP signed the written informed consent
form. The study and the informed consent form were
approved by the Ethics Committee of the University




The recruitment and study procedure is illustrated in
Figure 1. At baseline assessment (T0) we received
1433 BP protocols. The data of 76 patients were
excluded because they did not fulfil the inclusion
criteria (not a member of a statutory health insurance, no
repeated antihypertensive medication) or because of
missing questionnaires. Hence data of 1357 patients
remained. Then 237 Patients (17.5%) were excluded
because they fulfilled two conditions: (1) Their hyperten-
sion was characterised as controlled treated (defined as 24h
mean < 130/80 mmHg and daytime mean < 135/85 mmHg
and night mean < 120/70 mmHg [1,31]) and (2) they had
no relevant comorbidity (diabetes mellitus, coronary heart
disease [CHD]/heart attack, stroke/transient ischaemic
attack [TIA] or peripheral arterial occlusive disease [PAOD]).
Hence 1120 patients with uncontrolled but treated
hypertension and/or at least one relevant comorbid
disorder continued in the study.
Then, the 37 GP practices were randomised to
intervention and control group. Immediately before
the intervention one GP of the intervention group
opted out. This GP practice did not transfer any patient
data. In total 17 GP practices received the intervention, 19
GP practices belonged to the control group. These GPs
treated their patients as usual. After the T0 assessmentwas completed and before the T1 assessment started, the
intervention (SDM training) took place. In total, the
analysis sample included the data of 1120 patients:
552 patients of 17 GP practices in the intervention
group and 568 patients of 19 GP practices in the
control group. The mean cluster size in T0 amounted to
32.5 patients in the intervention group (range 5–46) and
in the control group 29.9 patients (range 8–53); the
development of the cluster sizes in the course of the study
is shown in Figure 1.
In the intervention group 171 patients missed at least
one follow-up measurement. Thereof, 88 patients took
part in T0 only and were completely lost to follow up
(15.9%). Another 83 patients took part in T0 and in at
least one of T1, T2 or T3 (15.0%). Data of the latter
patients were included in the mixed models if values for
the corresponding endpoints had been available. In the
control group 211 patients (37.1%) missed at least one
follow-up measurement. Of these, 86 patients were
completely lost to follow-up (15.1%). Another 125 patients
took part in at least one follow-up measurement so that
their data were included in the mixed models (22.0%). The
number of patients lost to follow-up is illustrated in
Figure 1 and the number of patients available for
each analysis is listed in Table 1.
Patient characteristics at baseline T0
Patients’ mean age was 63.8 years (± 12.1) in the inter-
vention group, and 65.0 years (± 12.4) in the control
group (cf. Table 2). In the intervention group 46.7% of
patients were male, compared to 44.7% in the control
group. At T0 41.1% of the patients in the intervention
group vs. 48.8% of the patients in the control group had
at least one relevant comorbidity.
Perceived participation (SDM-Q-9) at T0 was rela-
tively high both in the intervention group (mean score
73.00 [± 17.66]) and in the control group (mean score
70.67 [± 20.24]). Patients in both groups reported a very
high medication adherence (MARS-D; mean score about
94 in both groups).
The 24h mean systolic / diastolic BP at T0 amounted
to 133.2/82.0 mmHg (± 13.6/± 9.8) in the intervention
group and 130.8/79.3 mmHg (± 12.6/± 9.7) in the
control group. Almost 90.8% of the patients (N = 501)
in the intervention group and 84.7% of patients (N = 481)
in the control group exceeded at least one of the six ABPM
thresholds (24 h or day or night), i.e. these patients were
characterised as ‘uncontrolled treated’. The 24h mean
systolic BP of patients with uncontrolled hypertension in
the intervention group amounted to 134.9 mmHg (± 12.8)
and for the control group to 133.5 mmHg (± 11.5). The
24h mean systolic BP of all patients characterised as
controlled hypertensive but with relevant comorbidity
(12.2%, N = 138) was considerably lower and amounted to
17 GP practices, 463 patients***
Mean patients per GP 
practice : 27.2 (range: 2-41)
T0 ABPM screening: valid data of 1357 patients
T0 analysis sample: 36 GP practices; 1120 patients
Exclusion
237 patients were 
controlled treated and 
had no comorbidity
(17.5%)
17 GP practices, 427 patients***
mean patients per GP 
practice: 25.1 (range: 2-38)
17 GP practices, 381 patients***
mean patients per GP 
practice: 22.4 (range: 2-34)
18 GP practices, 419 patients***
mean patients per GP 
practice: 23.2 (range: 7-47)
18 GP practices, 357 patients***
mean patients per GP
practice: 19.8 (range:4-34)
1962 patients asked to take part in the study
T0 data assessed: 37 GP practices, 1433 patients
529 patients not 
willing to take part 
(27.0%)
19 GP practices, 478 patients***
Mean patients per GP 
practice: 25.2 (range: 7-51)
GP practices: Participation list = 45
Randomisation: 37 GP practices
Intervention:18 GP practices / Control:19 GP practices
10 GP practices 
discontinued*
GP practices:  Participation list = 35 +5 (waiting list)
3 GP practices 
discontinued *
Study participation: 37 GP practices
Randomisation of GP practices to participation list and waiting list
68 interested GP practices
Intervention
SDM training
1 GP* practice discontinued
0 Patients
Intervention group
17 GP practices, 552 patients
Mean patients per GP 
practice: 32.5 (range: 5-53)
Control group
19 GP practices, 568 patients
Mean patients per GP 
practice: 29.9 (range: 8-53)
Exclusion
76 invalid patients (5.3%)**






T0 Data of 1120 patients
Figure 1 (See legend on next page.)
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Figure 1 Recruitment and study procedure including loss to follow-up. GP practices = general practitioner practices. * Details of
discontinued GP practices: high work load and lack of staff. ** Details of invalid data: Enrolment in contrary to the inclusion criteria
(patients were not member of a statutory health insurance or had not received repeated antihypertensive medication) or questionnaires were missing.
*** Details of discontinued patients in both study arms: 1) Intervention group: 171 patients missed at least one follow-up (31.0%). Thereof data of
88 patients are completely lost (15.9%) (loss of T1, T2, and T3) and data of 83 patients (15.0%) are partially available (loss of T1, T2 or T3). 2) Control
group: 211 patients missed at least one follow-up (37.1%; including 1 GP practice* with 3 active patients). Thereof data of 86 patients are completely
lost (15.1%) (loss of T1, T2, and T3) and data of 125 patients (22.0%) are partially available (loss of T1, T2, or T3). Number of patients available for each
analysis is listed in Table 1. Reasons for discontinuation of the patients: patients’ desire (N = 241), change of GP practice (N =18), cardiovascular death
(N = 2), other death (N =10), loss of GP practice (3 patients), other cause (N = 65), missing Documentation (N = 41).
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115.8 mmHg (± 6.7) in the control group.
After the first ABPM and the following adaptation of
the therapy in T0, the mean BP values (systolic/diastolic)
in the whole sample decreased by 3.4/2.4 mmHg toTable 1 Mean changes of endpoints at each follow-up to base
(effect estimates)
Mean changes Intervention group Control group
Number of GP practices 17 17 17 19 18
Primary endpoints
SDM-Q-9 T1-T0 T2-T0 T3-T0 T1-T0 T2-T0
Valid N 320 287 256 337 272
Mean change −0.11 −2.875 −1.07 −4.06 −2.34
(SD) (21.45) (22.98) (21.50) (22.51) (20.73) (
Systolic BP T2-T1 T3-T1 T2-T1
Valid N 414 381 376
Mean change in mmHg 0.59 0.43 −0.02
(SD) (11.54) (12.08) (10.60) (
Secondary endpoints
Diastolic BP T2-T1 T3-T1 T2-T1
Valid N 414 381 376
Mean change in mmHg −0.20 −0.15 −0.15
(SD) (6.74) (6.14) (6.14)
CVR T2-T1 T3-T1 T2-T1
Valid N 294 282 255
Mean change in % 0.71 1.44 1.14
(SD) (5.43) (6.89) (5.58)
MARS-D T2-T1 T3-T1 T2-T1
Valid N 360 320 313
Mean change 0.07 0.4 −0.3
(SD) (9.6) (10.7) (6.9)
Knowledge T1-T0 T2-T0 T3-T0 T1-T0 T2-T0
Valid N 446 402 363 428 369
Mean change 3.00 2.99 5.85 3.30 3.76
(SD) (27.71) (28.56) (28.44) (30.00) (28.37) (
BP Blood Pressure, SDM-Q-9 Shared Decision Making-Questionnaire, CVR cardiovasc127.9/78.0 mmHg (±12.2/±9.4) at T1. This decrease can-
not result from the intervention because the intervention
could have affected BP values after the T1 consultation at
the earliest. The baseline BP value (T1) in the intervention
group amounted to 128.9/79.2 mmHg (±12.5/±9.5) and inline and differences in average mean changes
Difference in average




























4.66 1.3267 −4.3272; 6.9806 0.6454
24.49)
ular risk, MARS-D Medication Adherence Report Scale-German Version.
Table 2 Patient characteristics at T0
Characteristics at T0 Intervention group Control group
(N =552) (N = 568)
Age mean (SD) 63.8 (± 12.1) 65.0 (± 12.4)
Gender: male % (N) 46.7% (258) 44.7% (254)
Educational level (Total valid N) (523) (521)
low 62.7% (328) 63.8% (332)
middle 24.1% (126) 22.6% (118)
high 13.2% (69) 13.6% (71)
ABDM (Total valid N) (552) (568)
24h-mean systolic (SD) 133.19 (13.58) 130.80 (12.62)
24h-mean diastolic (SD) 81.98 (9.77) 79.29 (9.74)
Uncontrolled hypertension 90.8% (501) 84.7% (481)
≥ 1 Comorbidity 41.1% (227) 48.8% (277)
Diabetes mellitus 23.7% (131) 32.6% (185)
Heart attack / CHD 16.8% (93) 20.8% (118)
Stroke/ TIA 4.7% (26) 5.5% (31)
Peripheral arterial occlusive disease 3.6% (20) 4.1% (23)
Manifest arteriosclerosis (heart attack, CHD, stroke, TIA, or PAOD) 22.6% (125) 26.4% (150)
CVR score in % (Total valid N) (420) (377)
Mean (SD) 20.40 (± 19.1) 22.85 (± 18.71)
BMI (Total valid N) (545) (561)
Mean (SD) 28.58 (± 4.78) 28.58 (± 4.79)
Smoking (Total valid N) (544) (558)
Positive (N) 11.2% (861) 11.6% (65)
Family history of CVD (Total valid N) (528) (527)
Positive (N) 24.2% (128) 19.4% (102)
Treatment outside the GP praxis 35.3% (195) 35.0% (199)
SDM-Q-9* (Total valid N) (451) (489)
Mean (SD) 73.00 (± 17.66) 70.67 (± 20.24)
Intention-to-treat-hypertension scale* (Total valid N) (521) (527)
Mean (SD) 80.61 (± 13.32) 79.79 (± 13.52)
MARS-D*(Total valid N) (531) (539)
Mean (SD) 93.9 (± 9.8) 93.5 (± 10.1)
Knowledge* (Total valid N) (536) (547)
Mean (SD) 46.63 (± 27.60) 44.22 (± 28.64)
* Scale 0 – 100 (0 = lowest level and 100 = highest level).
ABPM ambulatory blood pressure monitoring, CHD coronary heart disease, TIA transient ischemic attack, PAOD peripheral arterial occlusive disease,
CVR cardiovascular risk, BMI Body Maas Index, CVD, cardiovascular disease, SDM-Q-9 Shared Decision Making-Questionnaire, MARS-D Medication Adherence Report
Scale-German Version.
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(cf. Table 3). Even though the mean BP values in
both study arms were below recommended BP values
for ABPM in T1, the proportion of patients with uncon-
trolled (but treated) hypertension (as defined: at least one
of the six ABPM thresholds was exceeded) in the interven-
tion group amounted to 76.9% (N = 356) and in the control
group to 71.6% (N= 327) (cf. Table 4).Effects of the SDM training on primary endpoints
Effect on patients’ perceived participation (SDM-Q-9)
At baseline assessment (T0), the intervention group had
a slightly higher mean SDM-Q-9 score than the control
group (cf. Figure 2). The mean SDM-Q-9 score in the
control group decreased after baseline assessment. The
patients of the control group perceived the highest par-
ticipation after the first consultation reviewing the
Table 3 Patient characteristics at each assessment point
Intervention group Control group
T0 T1 T2 T3 T0 T1 T2 T3
Number GP practices 17 17 17 17 19 19 18 18
Primary endpoints
SDM-Q-9
Total valid Nr 451 363 333 301 489 368 295 269
Mean 73.00 73.03 70.51 71.71 70.67 66.55 67.20 66.60
(SD) (17.66) (19.54) (20.98) (20.59) (20.24) (21.34) (20.00) (20.71)
Systolic BP
Total valid N 552 463 418 383 568 457 394 348
Mean in mmHg 133.19 128.86 129.27 128.68 130.80 126.98 126.62 125.98
(SD) (13.58) (12.51) (12.80) (11.42) (12.62) (11.75) (12.29) (11.23)
Secondary endpoints
Diastolic BP
Total valid N 552 463 418 383 568 457 394 348
Mean in mmHg 81.98 79.21 79.07 78.55 79.29 76.75 76.75 75.64
(SD) (9.77) (9.49) (8.79) (8.81) (9.74) (9.10) (9.10) (8.46)
CVR
Total valid N 420 364 320 312 377 336 270 233
Mean in % 20.40 21.02 22.33 23.92 22.85 23.54 24.03 24.34
(SD) (18.15) (18.61) (18.82) (19.10) (18.71) (19.19) (19.23) (19.60)
MARS-D
Total valid N 531 419 387 349 539 408 357 326
Mean 93.9 95.4 96.0 96.1 93.5) 96.0 96.1 95.3
(SD) (9.8) (8.8) (6.8) (8.0) (10.1) (6.3) (6.8) (7.5)
Knowledge 536 455 412 371 547 444 382 343
Total valid N 536 455 412 371 547 444 382 343
Mean 46.63 50.05 50.18 53.34 44.22 47.04 47.64 48.51
(SD) (27.60) (28.39) (28.32) (28.21) (28.64) (30.11) (30.49) (30.15)
BP Blood Pressure, SDM-Q-9 Shared Decision Making-Questionnaire, CVR cardiovascular risk, MARS-D Medication Adherence Report Scale-German Version.
Table 4 Patients with uncontrolled (but treated) blood pressure from T0 to T3
Uncontrolled BP*: percentage Intervention group Control group
T0 Total valid numbers N 552 568
Uncontrolled BP Valid percentages % (number N ) 90.8% (501) 84.7% (481)
T1 Total valid numbers N 463 457
Uncontrolled BP Valid percentages % (number N ) 76.9% (356) 71.6% (327)
T2 Total valid numbers N 418 394
Uncontrolled BP Valid percentages % (number N ) 78.2% (327) 69.0% (272)
T3 Total valid numbers N 383 348
Uncontrolled BP Valid percentages % (number N ) 78.3% (300) 69.8% (243)
*Uncontrolled BP: if 24h-mean ≥ 130/80 mmHg or day-mean ≥ 135 /85 mmHg or night-mean ≥ 120/70 mmHg.
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Figure 2 Perceived participation measured by SDM-Q-9 in
intervention and control group from T0 (baseline) to T3.
Figure 4 Systolic blood pressure from T0 (screening value), and
T1 (baseline) to T3 in intervention and control group.
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http://www.biomedcentral.com/1471-2296/14/135ABPM protocol. In the intervention group the mean
SDM-Q-9 score remained approximately on the same level
at T1 but it also decreased slightly after T1 (cf. Figure 3).
After the intervention, the average decrease of the
SDM-Q-9 score was slightly smaller in the intervention
group than in the control group. According to the mixed
model analysis, the average change from T0 was 3.11 points
higher in the intervention group than in the control group
(97.5% CI [−2.37; 8.61], p = 0.203). The effect was not signifi-
cant at the (Bonferroni-corrected) 2.5% level (cf. Table 1).
Effect on systolic blood pressure
In all four data assessments the mean systolic BP was
slightly higher in the intervention group than in the con-
trol group (cf. Figure 4 and Table 3). Distinct decreases
in BP could be observed in both study arms between T0
and T1, i.e. after the initial assessment, and a possible
change in patient’s treatment (cf. Figure 4). BPFigure 3 Average change of SDM-Q-9 from T1, T2, and T3
relative to T0 (baseline) in intervention and control group.measurements at T2 and T3, which were expected to be
affected by the SDM training, did not show relevant
changes compared to T1 (cf. Figure 5). The average
change in BP from T1 was – according to the mixed
model analysis – higher in the intervention group
than in the control group (effect estimate +1.75
mmHg (97.5% CI [−0.189; 3.69], p = 0.043). This resulted
from a slight BP decrease in the control group and a slight
BP increase in the intervention group (cf. Table 1).
The comparative increase of systolic BP in the inter-
vention group was against our expectations. However,
it is not significant at the level of 2.5%. The sensitiv-
ity analyses with (1) baseline T0 and (2) 12 additional
prognostic factors showed similar trends with average
intervention effects of +1.07 mmHg (97.5% CI [0.76; 2.90])
and +2.39 mmHg (97.5% CI [0.23; 4.53]), respectively.Figure 5 Average change of systolic blood pressure from T2
and T3 relative to baseline (T1) in intervention and
control group.
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the positive (but not significant) intervention effect on
participation resulted from a decreased participation in the
control group rather than an increase in the intervention
group. And (2) a comparative (but not significant) increase
of systolic blood pressure was observed in the intervention
group compared to the control group.
Effects of the SDM training on secondary endpoints
The mean changes in secondary endpoint variables were
very small, and there was no significant intervention ef-
fect on any of these endpoints (at significance level 5%).
The intervention led to a negligible decrease of 0.49% in
CVR (95% CI [−1.43; 0.45], p = 0.308) in the intervention
group compared to the control group. The knowledge of
the patients about hypertension increased slightly in
both study arms. However, the mean intervention effect
amounted to only +1.33 points (95% CI [−4.33; 6.98],
p = 0.645) and was not significant. The mean adherence
score (MARS-D) was very high at the beginning of the
study (cf. Table 3), thus leaving little potential for
improvement. The mean intervention effect (cf. Table 1)




The results of this study showed that the SDM training
programme for GPs neither enhanced patients’ participation
significantly nor contributed to a BP decrease, to a higher
adherence or knowledge. The CVR-lowering effect of the
SDM training amounted to 0.49% (p = 0.308), was negli-
gible and not significant. Deviating from our hypothesis the
SDM training did not show any relevant effect on primary
or secondary endpoints. Instead, the implementation
of the ABPM initiated an improvement of the hyper-
tension treatment, followed by a mean BP decrease
between T0 and T1 by (systolic/diastolic) 3.4/4.4 mmHg
(±12.2/±9.4) in all patients.
Strengths and weaknesses of the study
Because most of the participating GPs were academic
family doctors associated with the Division of General
Practice of the University Medical Centre Freiburg
(Germany), the external validity of our results seems to
be limited. Therefore we may assume that the participating
GPs are probably more open-minded as to taking part in
studies and improving their skills when compared to all
GPs in the region. Thus, e.g., we assume that GPs who were
interested in improving their antihypertensive treatment
or their communication skills were overrepresented in
this study.
The internal validity of the study is limited to some
extent because the intervention itself could not beblinded for the GPs. With respect to the endpoint
‘patients’ perceived participation’ our study might also
be internally limited: Recent discussions about the
SDM-Q-9 instrument have raised doubts about its
content validity [48,49]. Nevertheless the internal validity
of the data seems to be fairly high. The loss to follow-up
in primary care studies with long term follow up is higher
than in clinical studies and was taken into consideration
in our sample size calculation. In both arms of this study
about 15% of the patients were completely lost to follow-
up (15.9% in the intervention group and 15.1% in the
control group). Another 15% in the intervention group
and 22% in the control group were lost at one or two
of the three follow-ups. In the power calculation we esti-
mated that 788 patients would finish the T3 assessment –
and this number was nearly achieved (N = 738). In total the
missing patterns were rather similar in both study arms.
Additionally, the implementation of a cluster-randomised
design and a rigorous statistical analysis reinforce the
evidence of the results. Therefore the results of our study
seem sufficiently valid.
It would have been desirable to evaluate to what extent
the GPs in the intervention group really implemented a
communication style in accordance with the SDM princi-
ples. As we measured only patients’ perceptions on the
subject, we do not know to what extent the GPs of the
intervention group changed their behaviour ‘objectively’.
Comparison with other studies and interpretation
In comparison with other studies in which an SDM
intervention had been effective [15,17,24] our GP training
was rather short. Reviews investigating the effects of SDM
interventions ascertain that it is often difficult to bring
about behavioural change in doctors with short training
programmes [20,21]. Thus one could argue that a more
intensive training or other dissemination strategies like
coaching on the job or internet-driven feedback strategies
might be useful to change GPs’ communication behaviour.
However in the study by Deinzer et al. [25], which was
characterised by an SDM programme for GPs with a 16h
communication training plus supervision, the intervention
neither enhanced participation nor improved BP control. A
Cochrane review from 2010 analysed various educational
training programmes (not confined to SDM training)
directed to physicians to improve antihypertensive
treatment and did not find any effective training which
significantly lowered patients’ BP [50]. A recent review
concluded that to date there were no consistent results
regarding the effectiveness of patient participation on
health-related outcomes [51].
From prior process evaluations of our SDM training we
may presume that the intervention was sufficiently accepted
by the participating GPs. An intensive and ‘invasive’ training
or a direct evaluation of consultations, however, would
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and the feasibility of the study.
Our finding that BP decreased between T0 and T1 is in
line with other studies which showed that the implementa-
tion of ABPM contributed to a more effective antihyperten-
sive treatment [52-54]. However, it is necessary to take into
consideration that at T0 the mean 24h BP values of the
whole sample only marginally exceeded the recommended
ABPM thresholds. Moreover, the consultation that immedi-
ately followed the ABPM at T0 provided the opportunity to
GPs and patients to optimise their antihypertensive therapy
with all usual treatment options in both study arms before
the SDM training for GPs started. Accordingly, in T1 the
mean 24h BP values were even below the ABPM diagnostic
thresholds in both study arms. This might indicate that
systolic or diastolic BP values of most patients whose
hypertension was characterised as treated but uncontrolled
in T1 (intervention group: 76.9% [N = 356], control
group: 71.6% [N = 327], cf. Table 4) probably exceeded
the recommended ABPM thresholds – e.g. at night – only
marginally. Taking into account these circumstances,
aggressive treatment escalations could not be expected for
the majority of the study population after T1. Therefore
one could expect only relatively minor treatment responses
to further treatment changes on mean BP.
Conclusion
Considering that a distinct BP decrease could be noticed in
both study groups at the very beginning of the study, i.e.
between T0 and T1, we may put forward the hypothesis
that the implementation of ABPM can lead to a therapeutic
adaption with a positive effect on BP optimisation. The
subsequent implementation of a rather short SDM training
for GPs does obviously not increase the effectiveness of
such a therapeutic adaptation regarding BP decrease.
Though well accepted by the GPs, our results seem to
discourage the optimistic expectation that SDM training for
GPs solely leads to a relevant increase in patients’ perceived
participation or an improvement of clinical outcomes. As
patient participation is established in law in Germany,
further research should be undertaken to examine the
process of patient participation in primary care.
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